Adam Lerner MD
Professor, Hematology & Medical Oncology
Professor, Pathology & Laboratory Medicine
650 Albany St | (617) 638-7504
Hematology & Medical Oncology
BU-BMC Cancer Center
Evans Center for Interdisciplinary Biomedical Research
Dr. Lerner is a Professor of Medicine, Pathology and Laboratory Medicine at Boston University School of Medicine (BUSM) and a medical oncologist at Boston Medical Center (BMC). He received his MD from Yale School of Medicine, followed by an internal medicine residency at Boston City Hospital. He did his fellowship in Medical Oncology at the Dana Farber Cancer Institute, Harvard Medical School, and subsequently remained there while carrying out research in the cellular and molecular biology of T lymphocytes. In 1996, he joined the Hematology/Oncology Section at Boston Medical Center. His laboratory research has focused in two areas: 1) The therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in lymphoid malignancies; 2) The mechanism by which a novel adapter protein (BCAR3/ AND-34) modulates focal adhesion complex signaling in mesenchymal, epithelial and hematopoietic cells. Clinically, Dr. Lerner cares for patients with hematologic malignancies, cutaneous malignancies and sarcomas.
Expertise includes: CLL; Leukemia; Lymphoid malignancies; Sarcoma; Breast cancer; cAMP signaling.
MD, Yale University School of Medicine, 1983
AB, Amherst College, 1979
Milrod CJ, Blevins F, Hughes D, Lerner A, Sarosiek S, Sanchorawala V, Sloan JM. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs. Blood. 2021 May 27; 137(21):2987-2989. PMID: 33728443.Published on 9/8/2020
Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q, Kataria Y, Sarosiek SR, Lerner A, Sloan JM, Quillen K, Burks EJ. SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis. Am J Clin Pathol. 2020 09 08; 154(4):466-474. PMID: 32681166.Published on 5/27/2020
Dennis M, Maoz A, Cirstea D, Patel A, Lerner A, Sarosiek S. Treatment disparities in minority groups with multiple myeloma at a safety-net hospital. Leuk Lymphoma. 2020 10; 61(10):2507-2510. PMID: 32460648.Published on 1/31/2019
Leiva O, McMahon L, Sloan JM, Lee J, Lerner A. Recognition of hemophagocytic lymphohistiocytosis in sickle cell vaso-occlusive crises is a potentially lifesaving diagnosis. Haematologica. 2019 04; 104(4):e167-e169. PMID: 30705096.Published on 1/15/2018
Min MS, Al-Haseni A, Succaria F, Goldberg L, Lerner A, Sahni D. Anaplastic large cell lymphoma localized to the left breast years after radiotherapy for breast cancer. Dermatol Online J. 2018 Jan 15; 24(1). PMID: 29469762.Published on 9/1/2017
de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Dec; 40:73-80. PMID: 28867658.Published on 8/30/2017
Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018 04; 59(4):880-887. PMID: 28853310.Published on 8/10/2016
Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk. 2016 Nov; 16(11):637-643. PMID: 27637428.Published on 6/13/2016
Xu C, Wyman AR, Alaamery MA, Argueta SA, Ivey FD, Meyers JA, Lerner A, Burdo TH, Connolly T, Hoffman CS, Chiles TC. Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes. Int Immunopharmacol. 2016 Sep; 38:223-32. PMID: 27302770.Published on 10/13/2015
Dong H, Carlton ME, Lerner A, Epstein PM. Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells. Front Pharmacol. 2015; 6:230. PMID: 26528184.